Catatonia: clinically important change in catatonia symptoms (improved at least 50% on the VAS) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Mental state · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: use of antiparkinsonism drugs · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes adverse effects: use of antiparkinsonism drugs compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Deterioration · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events: extrapyramidal symptoms (need of antiparkinsonism drugs) · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: general adverse events (UKU Average change score) · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: not improved to a clinically important extent compared with other drugs (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes tardive dyskinesia: deterioration of symptoms compared with other drugs (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review